1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in the United States, July 2019

Biotechnology Analysis & Statistics in the United States, July 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Firstword Pharma

All regions

data types

1-30 of 47 reports

Breast Cancer: KOL Insight [2018]

Breast Cancer: KOL Insight [2018]

  • $ 9000
  • Industry report
  • May 2018

How is biosimilar trastuzumab expected to fare in breast cancer?Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected to fare afte ...

  • Industries : Medical Biotechnology, Therapy
  • Countries : United States
Psoriasis: Update Bulletin #3 [April 2018]

Psoriasis: Update Bulletin #3 [April 2018]

  • $ 1151
  • Industry report
  • April 2018

This edition presents key opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; KOL views on AbbVie’s presentation of positive results from two pivotal ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]

CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]

  • $ 9000
  • Industry report
  • April 2018

How are CAR-T cell therapies revolutionising treatment of haematological cancer?Last year witnessed the FDA approval of the first two anti-CD19 CAR-T cell therapies in two types of blood cancer. Find out ...

  • Industries : Therapy
  • Countries : United States
Biosimilars: US Payer Perspectives (2018)

Biosimilars: US Payer Perspectives (2018)

  • $ 2651
  • Industry report
  • April 2018

US payers eye European biologics market with envyBiosimilars may be a roaring success in Europe but the picture in the US couldn’t be more different. Once hailed as a solution to stem the tide of soaring ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Rheumatoid Arthritis: KOL Insight [2018]

Rheumatoid Arthritis: KOL Insight [2018]

  • $ 9000
  • Industry report
  • March 2018

How is Olumiant impacting the RA treatment landscape?After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, Eli Lilly/Incyte’s ...

  • Industries : Medical Biotechnology, Health Services
  • Countries : United States, United Kingdom, Netherlands
Malignant Melanoma: Update Bulletin

Malignant Melanoma: Update Bulletin

  • $ 1151
  • Industry report
  • February 2018

Gain new key opinion leader (KOL) insights on the latest events happening in melanoma. Topics covered include expert opinions on; results of thePhase III EORTC1325/KEYNOTE-054 trial investigating pembrolizuma ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • Industry report
  • February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America, United Kingdom
Market Access Impact: Psoriasis (US) 2018

Market Access Impact: Psoriasis (US) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect nearly 30% of psoriasis prescriptions. Is your brand losing out?In the US, where market barriers affect nearly 30% of all psoriasis prescriptions, the top brand has a significant ...

  • Industries : Biotechnology
  • Countries : United States
Market Access Impact: Ulcerative Colitis (US) 2018

Market Access Impact: Ulcerative Colitis (US) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect 15% of ulcerative colitis prescriptions. Is your brand losing out?In the US, where market barriers affect 15% of all ulcerative colitis prescriptions, the top two brands have a significant ...

  • Industries : Biotechnology
  • Countries : United States
Market Access Impact (US) [RA]

Market Access Impact (US) [RA]

  • $ 5637
  • Industry report
  • November 2017

Who wins and loses when brands struggle with cost barriers and limited market access?Market barriers affect just over 20 percent of rheumatoid arthritis (RA) prescriptions in the US. High costs and limited ...

  • Industries : Medical Biotechnology
  • Countries : United States
The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

  • $ 2537
  • Industry report
  • September 2017

The Future of Biosimilars in the USACan pharma resolve the litigation frenzy hampering biosimilars’ market entry in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Psoriasis 2017

Psoriasis 2017

  • $ 8658
  • Industry report
  • July 2017

Will biosimilar anti-TNFs prevent novel therapies from gaining traction? As the use of biosimilar anti-TNFs continues to expand access , and lower the costs of, biologic therapies in the treatment fo ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
NPS+ Growth Hormone Deficiency (US) 2017

NPS+ Growth Hormone Deficiency (US) 2017

  • $ 2844
  • Industry report
  • July 2017

Why are some US GHD brands standing out more than others? There are various options available to US endocrinologists to treat growth hormone deficiency (GHD). Clearly some of these options are achieving ...

  • Industries : Medical Biotechnology
  • Countries : United States
Market Access Impact (US) [Growth Hormone Deficiency]

Market Access Impact (US) [Growth Hormone Deficiency]

  • $ 5637
  • Industry report
  • June 2017

What stops doctors from prescribing your brand? It may be more than one thingMarket barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. ...

  • Industries : Medical Biotechnology
  • Countries : United States
Biosimilars: US Payer Perspectives

Biosimilars: US Payer Perspectives

  • $ 2537
  • Industry report
  • April 2017

Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Rheumatoid Arthritis [2017]

Rheumatoid Arthritis [2017]

  • $ 8658
  • Industry report
  • April 2017

How are biosimilar anti-TNFs faring? Will your brand be affected?After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now looks ...

  • Industries : Medical Biotechnology
  • Countries : United States, United Kingdom, European Union
HNSCC: KOL Insight - 2017

HNSCC: KOL Insight - 2017

  • $ 8658
  • Industry report
  • March 2017

DescriptionHow will immunotherapy continue to shape the HNSCC treatment landscape?The availability of Merck &Co.’s Keytruda and BMS’ Opdivo has already transformed the second-line treatment of head ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical
  • Countries : United States, United Kingdom
Market Access Impact (US) [PsO]

Market Access Impact (US) [PsO]

  • $ 5637
  • Industry report
  • March 2017

DescriptionTop brand takes a big lead thanks to market barriersIn the US, market barriers are having a major impact on the brands used to treat psoriasis—affecting more than a third of all prescriptions ...

  • Industries : Biotechnology
  • Countries : United States
Targeted Therapies in Asthma - 2017

Targeted Therapies in Asthma - 2017

  • $ 8658
  • Industry report
  • February 2017

DescriptionAs new targeted asthma therapies emerge, is time running out for Xolair?Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States
Biosimilars Education: Addressing a significant unmet need

Biosimilars Education: Addressing a significant unmet need

  • $ 2537
  • Industry report
  • November 2016

DescriptionHow to educate stakeholders about biosimilar benefitsWhat information and data do physicians, payers and patients need about biosimilars? benefitsAs the market expands and new therapeutic sectors ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union, World
Multiple Sclerosis: KOL Insight 2016

Multiple Sclerosis: KOL Insight 2016

  • $ 8658
  • Industry report
  • November 2016

DescriptionBig changes ahead as Ocrevus nears approval. How will it affect your brand?Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the ...

  • Industries : Medical Biotechnology, Health Services
  • Countries : United States, Canada, Denmark
Benchmarking Biologic Innovator Value-Added-Services

Benchmarking Biologic Innovator Value-Added-Services

  • $ 2537
  • Industry report
  • November 2016

DescriptionDelivering high-quality value-added services for biologicsWhat are the “beyond-the-pill” services that biologic companies need to deliver to ensure improved patient compliance and outcomes?Patient, ...

  • Industries : Medical Biotechnology
  • Countries : United States
NPS+ Growth Hormone Deficiency (GHD) (US)

NPS+ Growth Hormone Deficiency (GHD) (US)

  • $ 2765
  • Industry report
  • July 2016

Could differentiation efforts boost some GHD brands in the US?Opportunity lurks in the US Growth hormone Deficiency treatment landscape. Although 3 established brands dominate, promoters of these brands ...

  • Industries : Medical Biotechnology
  • Countries : United States
The Future of Biosimilars 2016

The Future of Biosimilars 2016

  • $ 2445
  • Industry report
  • July 2016

Development activity is surging as the focus shifts to commercialisation. How will the market evolve?The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
NPS+ Psoriasis (EU5)

NPS+ Psoriasis (EU5)

  • $ 2765
  • Industry report
  • April 2016

Psoriasis: NPS results for psoriasis treatments show clear winners and losers. How does your brand rank?Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of ...

  • Industries : Medical Biotechnology
  • Countries : United States
Breast Cancer: Update Bulletin [March 2016]

Breast Cancer: Update Bulletin [March 2016]

  • $ 1077
  • Industry report
  • March 2016

In this update KOLs reflect on the promising Phase Ib data for Roche’s monoclonal antibody (mAb), atezolizumab, in combination with nab-paclitaxel for patients with metastatic triple- negative breast ...

  • Industries : Therapy, Medical Biotechnology, Oncology
  • Countries : United States
Biosimilars in Oncology: Update Bulletin [Feb 2016]

Biosimilars in Oncology: Update Bulletin [Feb 2016]

  • $ 1077
  • Industry report
  • February 2016

New KOL insights on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz’s PROTECT 1 and PROTECT 2 studies which ...

  • Industries : Medical Biotechnology
  • Countries : United States
Ulcerative Colitis: Update Bulletin [Feb 2016]

Ulcerative Colitis: Update Bulletin [Feb 2016]

  • $ 1077
  • Industry report
  • February 2016

Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson’s Stelara (ustekinumab) in Crohn’s disease ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Therapy
  • Countries : United States, European Union
Biosimilars in Oncology: KOL Insight

Biosimilars in Oncology: KOL Insight

  • $ 8379
  • Industry report
  • January 2016

IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologists that make treatment decisions in life or death situations aren't yet ready to accept biosimilars ...

  • Industries : Medical Biotechnology, Therapy, Health Services, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States
Biosimilars: Regulatory Outlook

Biosimilars: Regulatory Outlook

  • $ 2337
  • Industry report
  • November 2015

Biosimilars offer a chance to improve access to, and reduce spending on, life-saving biologic therapies. But could regulators do more to support the market? While experts believe significant regulatory ...

  • Industries : Medical Biotechnology
  • Countries : United States, World, Europe

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on